Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Homozygous Familial Hypercholesterolemia (HoFH) - Overview
Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Homozygous Familial Hypercholesterolemia (HoFH) - Companies Involved in Therapeutics Development
AD Pharmaceuticals Co Ltd
Amryt Pharma Plc
Beijing Mabworks Biotech Co Ltd
Daewoong Co Ltd
Gemphire Therapeutics Inc
Innovent Biologics Inc
LIB Therapeutics LLC
Lipigon Pharmaceuticals AB
LipimetiX Development Inc
Madrigal Pharmaceuticals Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
The Medicines Company
Homozygous Familial Hypercholesterolemia (HoFH) - Drug Profiles
Homozygous Familial Hypercholesterolemia (HoFH) - Dormant Projects
Homozygous Familial Hypercholesterolemia (HoFH) - Discontinued Products
Homozygous Familial Hypercholesterolemia (HoFH) - Product Development Milestones
Appendix



List of Figures


Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by AD Pharmaceuticals Co Ltd, H2 2019
Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by Amryt Pharma Plc, H2 2019
Homozygous Familial Hypercholesterolemia (HoFH) - Dormant Projects, H2 2019
Homozygous Familial Hypercholesterolemia (HoFH) - Discontinued Products, H2 2019